Strides completes acquisition of Endo’s U.S. manufacturing facility

Strides has completed the acquisition of a manufacturing facility in Chestnut Ridge, N.Y. along with a basket of ANDAs from Endo International.

In August, Strides announced it had inked a definitive agreement with Endo for the acquisition, stating that “over the last few years, Strides U.S. business has seen a significant ramp up driven by portfolio expansion and strengthening of frontend presence. The United States is now the largest market for Strides contributing 48% of FY21 consolidated revenue."

[Read more: Strides Pharma gets FDA OK for generic Deltasone]

The acquisition is expected to further bolster Strides' U.S. presence through acquisition of a multi dosage facility in the U.S. and a basket of ANDAs cutting across multiple therapeutic segments.

[Read more: Strides gets FDA nod for generic URSO]

The facility has an annual capacity of 2 billion units across semisolids, liquids, nasal sprays along with oral solids. The facility also is registered with the Drug Enforcement Administration enabling manufacturing of controlled substances.

The acquired portfolio has 20 commercial products and a basket of dormant ANDA’s which the company noted "will help fast track our new launch strategy for U.S. markets with 5 to 6 new product introductions every quarter."